Karyopharm Theraps Drug Patent Portfolio
Karyopharm Theraps owns 1 orange book drug protected by 10 US patents Given below is the list of Karyopharm Theraps's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10519139 | Polymorphs of Selinexor | 14 Aug, 2035 | Active |
| US11746102 | Polymorphs of selinexor | 14 Aug, 2035 | Active |
| US11753401 | Polymorphs of Selinexor | 14 Aug, 2035 | Active |
| US11807629 | Polymorphs of Selinexor | 14 Aug, 2035 | Active |
| US8999996 | Hydrazide containing nuclear transport modulators and uses thereof | 03 Jul, 2033 | Active |
| US10544108 | Hydrazide containing nuclear transport modulators and uses thereof | 26 Jul, 2032 | Active |
| US11034660 | Hydrazide containing nuclear transport modulators and uses thereof | 26 Jul, 2032 | Active |
| US11787771 | Hydrazide containing nuclear transport modulators and uses thereof | 26 Jul, 2032 | Active |
| US9079865 | Hydrazide containing nuclear transport modulators and uses thereof | 26 Jul, 2032 | Active |
| US9714226 | Hydrazide containing nuclear transport modulators and uses thereof | 26 Jul, 2032 | Active |
Latest Legal Activities on Karyopharm Theraps's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Karyopharm Theraps.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Patent Issue Date Used in PTA Calculation
Critical
| 07 Nov, 2023 | US11807629 |
|
Recordation of Patent Grant Mailed
Critical
| 07 Nov, 2023 | US11807629 |
|
Email Notification
Critical
| 07 Nov, 2023 | US11807629 |
| Recordation of Patent eGrant | 07 Nov, 2023 | US11807629 |
| Mail Patent eGrant Notification | 07 Nov, 2023 | US11807629 |
| Patent eGrant Notification | 07 Nov, 2023 | US11807629 |
|
Email Notification
Critical
| 19 Oct, 2023 | US11807629 |
|
Issue Notification Mailed
Critical
| 18 Oct, 2023 | US11807629 |
|
Email Notification
Critical
| 17 Oct, 2023 | US11787771 |
| Patent eGrant Notification | 17 Oct, 2023 | US11787771 |
| Recordation of Patent eGrant | 17 Oct, 2023 | US11787771 |
|
Recordation of Patent Grant Mailed
Critical
| 17 Oct, 2023 | US11787771 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 17 Oct, 2023 | US11787771 |
| Mail Patent eGrant Notification | 17 Oct, 2023 | US11787771 |
| Dispatch to FDC | 30 Sep, 2023 | US11807629 |
Karyopharm Theraps's Family Patents
Karyopharm Theraps drugs have patent protection in a total of 37 countries. It's US patent count contributes only to 22.5% of its total global patent coverage. Click
below to unlock the full patent family tree.
Karyopharm Theraps Drug List
Given below is the complete list of Karyopharm Theraps's drugs and the patents protecting them.
1. Xpovio
Xpovio is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10519139 | Polymorphs of Selinexor |
14 Aug, 2035
(10 years from now)
| Active |
| US11746102 | Polymorphs of selinexor |
14 Aug, 2035
(10 years from now)
| Active |
| US11753401 | Polymorphs of Selinexor |
14 Aug, 2035
(10 years from now)
| Active |
| US11807629 | Polymorphs of Selinexor |
14 Aug, 2035
(10 years from now)
| Active |
| US8999996 | Hydrazide containing nuclear transport modulators and uses thereof |
03 Jul, 2033
(8 years from now)
| Active |
| US10544108 | Hydrazide containing nuclear transport modulators and uses thereof |
26 Jul, 2032
(7 years from now)
| Active |
| US11034660 | Hydrazide containing nuclear transport modulators and uses thereof |
26 Jul, 2032
(7 years from now)
| Active |
| US11787771 | Hydrazide containing nuclear transport modulators and uses thereof |
26 Jul, 2032
(7 years from now)
| Active |
| US9079865 | Hydrazide containing nuclear transport modulators and uses thereof |
26 Jul, 2032
(7 years from now)
| Active |
| US9714226 | Hydrazide containing nuclear transport modulators and uses thereof |
26 Jul, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xpovio's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List